Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.41 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11791788 | 0.93 | CA2 (0.45) | CA1SIRT6SIRT1NOD1CA2 | |
| SCHEMBL14819876 | 0.83 | GPR84 (0.42) | GPR84CA1FFAR1SIRT6SIRT1 | |
| SCHEMBL11057343 | 0.83 | NOD1 (0.56) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL8243242 | 0.83 | GPR84 (0.42) | GPR84CA1FFAR1SIRT6SIRT1 | |
| SCHEMBL14820006 | 0.81 | MMP3 (0.43) | GPR84CA1FFAR1SIRT6SIRT1 | |
| SCHEMBL24642434 | 0.81 | SIRT6 (0.44) | CA1SIRT6SIRT1CA2 | |
| SCHEMBL7100031 | 0.81 | NOD1 (0.59) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL14978808 | 0.81 | SIRT6 (0.55) | GPR84CA1FFAR1SIRT6SIRT1 | |
| SCHEMBL8253003 | 0.81 | GPR84 (0.45) | GPR84FFAR1SIRT6SIRT1ZDHHC7 | |
| SCHEMBL24767730 | 0.81 | GPR84 (0.45) | GPR84FFAR1SIRT6SIRT1ZDHHC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220273807-A1 | CONJUGATES FOR USE IN METHODS OF TREATING CANCER | ASTRAZENECA AB (SE) | 2022-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220273807-A1 | CONJUGATES FOR USE IN METHODS OF TREATING CANCER | CD44, FOLH1, SLC17A5 | GPR84 1793/4885CA1 396/4885FFAR1 3163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.